Frankfurt
20.12.24
15:29 Uhr
3,100 Euro
-0,400
-11,43 %
-11,43 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Nanobiotix S.A.: NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 | 1 | GlobeNewswire (USA) | ||
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| Di | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 09.12. | Nanobiotix S.A.: NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer | 155 | GlobeNewswire (Europe) | Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial23 months median Overall Survival from date... ► Artikel lesen | |
| 09.12. | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.11. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 4 | GlobeNewswire (USA) | ||
| 12.11. | Nanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms | 179 | GlobeNewswire (Europe) | Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submissionAdded expert industry leaders to Supervisory... ► Artikel lesen | |
| 11.10. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 5 | GlobeNewswire (USA) | ||
| 11.10. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 18.09. | Nanobiotix reports 1H results | 2 | Seeking Alpha | ||
| 18.09. | Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results | 231 | GlobeNewswire (Europe) | RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune... ► Artikel lesen | |
| 18.09. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.09. | Nanobiotix S.A.: NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth | 3 | GlobeNewswire (USA) | ||
| 03.09. | Nanobiotix S.A.: Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference | 2 | GlobeNewswire (USA) | ||
| 03.09. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.08. | Nanobiotix shares rated Buy by Guggenheim, focused on expanding cancer treatment applications | 1 | Investing.com | ||
| 09.07. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 3 | GlobeNewswire (USA) | ||
| 09.07. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.06. | Nanobiotix S.A.: Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy | 253 | GlobeNewswire (Europe) | Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; "ITT") who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later... ► Artikel lesen | |
| 21.05. | Nanobiotix S.A.: Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth | 361 | GlobeNewswire (Europe) | Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3Alignment of intent to transfer the sponsorship... ► Artikel lesen |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,079 | 0,00 % | XFRA LD6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCORE ONE LABS INC.... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,977 | +4,38 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,700 | +8,00 % | COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs | Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE... ► Artikel lesen | |
| AMYRIS | - | - | BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply | ||
| HALOZYME THERAPEUTICS | 45,870 | +1,93 % | 9 Analysts Have This To Say About Halozyme Therapeutics | ||
| ABCELLERA BIOLOGICS | 2,718 | -0,37 % | AbCellera Reports Q2 2024 Business Results | VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported... ► Artikel lesen | |
| GLOW LIFETECH | 0,035 | -4,11 % | Glow LifeTech Corp.: Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement | Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") announces that, further to its news release dated December... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 315,60 | +0,54 % | Bio-Rad Reports Third-Quarter 2024 Financial Results | HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results... ► Artikel lesen | |
| AVID BIOSERVICES | 11,800 | 0,00 % | Avid Bioservices, Inc: Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction | TUSTIN, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| BIOLINERX | 0,204 | +6,25 % | BioLineRx-Aktie erreicht 52-Wochen-Tief bei 0,21 US-Dollar | ||
| AADI BIOSCIENCE | 3,300 | +0,61 % | Aadi Bioscience +72%: NBC-Kursrakete startet über Nacht | Riesengeschenk kurz vor Weihnachten: Mitglieder des exklusiven Anlegerclubs No Brainer Club (NBC) und Teilnehmer eines Webinars feiern am Freitag eine sensationelle Kursrakete. Die Aktie von Aadi Bioscience... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,960 | -2,97 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates | BURLINGTON, Mass., Nov. 05, 2024(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,870 | +3,08 % | Applied Therapeutics Appoints John H. Johnson as Executive Chairman | Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | Nitches, inc: Nitches Inc. Updates Shareholders on Amazon Integration, GovX Integration, and 2025 Growth Strategy for InTheZone Labs | LAS VEGAS, NV / ACCESSWIRE / December 18, 2024 / Nitches Inc. (OTC PINK:NICH) is pleased to share key updates regarding the recent strides made with its InTheZone Labs brand, highlighting successful... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,020 | +5,70 % | Ovid Therapeutics Aktie: Trends im Geschäftsfeld | Die Ovid Therapeutics Aktie verzeichnete am 29. November 2024 einen positiven Handelstag mit einem Kursanstieg von 2,70 Prozent auf 1,14 USD. Diese Entwicklung kommt nach einer schwierigen Phase, in... ► Artikel lesen |
NANOBIOTIX SA ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,400 (-11,43 %) liegt der Kurs bei 3,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.
